Cargando…

Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review

The scarcity of novel and effective therapeutics for the treatment of cancer is a pressing and alarming issue that needs to be prioritized. The number of cancer cases and deaths are increasing at a rapid rate worldwide. Doxorubicin, an anticancer agent, is currently used to treat several types of ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Peter, Sijongesonke, Alven, Sibusiso, Maseko, Rejoice Bethusile, Aderibigbe, Blessing Atim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318127/
https://www.ncbi.nlm.nih.gov/pubmed/35889350
http://dx.doi.org/10.3390/molecules27144478
_version_ 1784755215156641792
author Peter, Sijongesonke
Alven, Sibusiso
Maseko, Rejoice Bethusile
Aderibigbe, Blessing Atim
author_facet Peter, Sijongesonke
Alven, Sibusiso
Maseko, Rejoice Bethusile
Aderibigbe, Blessing Atim
author_sort Peter, Sijongesonke
collection PubMed
description The scarcity of novel and effective therapeutics for the treatment of cancer is a pressing and alarming issue that needs to be prioritized. The number of cancer cases and deaths are increasing at a rapid rate worldwide. Doxorubicin, an anticancer agent, is currently used to treat several types of cancer. It disrupts myriad processes such as histone eviction, ceramide overproduction, DNA-adduct formation, reactive oxygen species generation, Ca(2+), and iron hemostasis regulation. However, its use is limited by factors such as drug resistance, toxicity, and congestive heart failure reported in some patients. The combination of doxorubicin with other chemotherapeutic agents has been reported as an effective treatment option for cancer with few side effects. Thus, the hybridization of doxorubicin and other chemotherapeutic drugs is regarded as a promising approach that can lead to effective anticancer agents. This review gives an update on hybrid compounds containing the scaffolds of doxorubicin and its derivatives with potent chemotherapeutic effects.
format Online
Article
Text
id pubmed-9318127
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93181272022-07-27 Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review Peter, Sijongesonke Alven, Sibusiso Maseko, Rejoice Bethusile Aderibigbe, Blessing Atim Molecules Review The scarcity of novel and effective therapeutics for the treatment of cancer is a pressing and alarming issue that needs to be prioritized. The number of cancer cases and deaths are increasing at a rapid rate worldwide. Doxorubicin, an anticancer agent, is currently used to treat several types of cancer. It disrupts myriad processes such as histone eviction, ceramide overproduction, DNA-adduct formation, reactive oxygen species generation, Ca(2+), and iron hemostasis regulation. However, its use is limited by factors such as drug resistance, toxicity, and congestive heart failure reported in some patients. The combination of doxorubicin with other chemotherapeutic agents has been reported as an effective treatment option for cancer with few side effects. Thus, the hybridization of doxorubicin and other chemotherapeutic drugs is regarded as a promising approach that can lead to effective anticancer agents. This review gives an update on hybrid compounds containing the scaffolds of doxorubicin and its derivatives with potent chemotherapeutic effects. MDPI 2022-07-13 /pmc/articles/PMC9318127/ /pubmed/35889350 http://dx.doi.org/10.3390/molecules27144478 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Peter, Sijongesonke
Alven, Sibusiso
Maseko, Rejoice Bethusile
Aderibigbe, Blessing Atim
Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
title Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
title_full Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
title_fullStr Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
title_full_unstemmed Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
title_short Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
title_sort doxorubicin-based hybrid compounds as potential anticancer agents: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318127/
https://www.ncbi.nlm.nih.gov/pubmed/35889350
http://dx.doi.org/10.3390/molecules27144478
work_keys_str_mv AT petersijongesonke doxorubicinbasedhybridcompoundsaspotentialanticanceragentsareview
AT alvensibusiso doxorubicinbasedhybridcompoundsaspotentialanticanceragentsareview
AT masekorejoicebethusile doxorubicinbasedhybridcompoundsaspotentialanticanceragentsareview
AT aderibigbeblessingatim doxorubicinbasedhybridcompoundsaspotentialanticanceragentsareview